Introduction {#sec1-1}
============

Oral squamous cell carcinoma (OSCC) is one the most common neoplasm of the head and neck (Zhou et al., 2016). An estimated 263,900 new cases and 128,000 deaths from oral cavity cancer (including lip cancer) occurred in 2008 worldwide (Ahmedin et al., 2011).

Several risk factors like use of tobacco, including smokeless tobacco and excessive consumption of alcohol are the major risk factors in oral cancer (Sankaranarayanan et al., 1999; Ko et al., 1995). Late diagnosis and resistance to radiotherapy, chemotherapy are the major cause of poor prognosis in oral cancer patients (Julianaet al., 2012). Recently, several studies have analyzed the biomarkers for predicting the prognosis of OSCC but no single study has found the appropriate result for clinical application.

Previously a microarray based study revealed that the expression of six genes including Paternally Expressed Gene 10 (PEG10) had significant up-regulation in OSCC cell line. This study had demonstrated that the significant expression of PEG10 was found in radioresistant cells when compared with radiosensitive cells in a dose and time dependent manner (Ishigami et al., 2007).

PEG10 was first identified by Ono et al., (2001). PEG10 is well-known as a paternally expressed gene from a newly recognized imprinted region at human chromosome 7q21. PEG10 shows parent of origin specific expression in monochromosomal hybrids (Ono et al., 2001; Sun et al., 2006). PEG 10 mRNA is expressed in normal tissues of brain, kidney, ovary, spleen, thymus, testis, lymphoblasts, endothelial cells and placenta (Okabeet al., 2003; Kainzet al., 2007). Okabeet al., (2003) found that overexpression of PEG10 may block TGF-β signaling pathway via binding to TGF-β receptors II and may cause decrease in cell death through interaction with SIAH1 (antisense S-oligonucleotides) in human hepatocellular carcinoma.

PEG10 is the essential protein for cell proliferation, migration, invasion, and its expression may help to predict the radiotherapy treatment response for the OSCC patients and their prognosis. In this study we examined the expression of PEG10 in OSCC and analyzed its expression in relation to clinicopathological features, radiotherapy treatment response and survival. We evaluated the prognostic significance of PEG10 in OSCC patients.

Materials and Methods {#sec1-2}
=====================

Study Population {#sec2-1}
----------------

We recruited 118 histopathologically confirmed tissue samples from OSCC patients (who were recommended for the Radiotherapy treatment) as well as eighty matched controls for the evaluation of PEG10 mRNA expression. Healthy matched individuals (n=80) attending dental procedures for dental implant or benign cyst were included as control group (for tissue samples). The tissue specimens were collected from the department of Radiotherapy and Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, India. The OSCC tissue specimens were derived from the buccal mucosa, tongue (excluding base of tongue), hard palate, floor of mouth, alveolus and lip. All the collected tissues were instantly stored in trizol solution at -80°C deep freezer. Ethical approval was obtained from the Institutional Ethics Committee (IEC number XLIV ECM/B-P11) before the start of the study. Informed written consent was taken from all the participants before their inclusion into the study. The characteristics of the OSCC patients including age, clinical stage (TNM classification defined by the American Joint Committee on Cancer AJCC 2010, VIIth edition) (Edge SB and Compton CC, 2010) and adverse oral habits (tobacco and alcohol) were assessed by radiation oncologist. Patients with more than 18 years of age, normal hematological, renal and liver function test were included. Patients with history of prior chemotherapy, radiotherapy and surgery and distant metastasis were excluded from the study.

Treatment and Response Assessment {#sec2-2}
---------------------------------

Patients of OSCC were subjected to radiotherapy using tele-cobalt radiotherapy machine (Theratron 780 E, AECL, Ottawa) in the Department of Radiotherapy. A dose of 70 Gy of radiation was delivered to all the patients in 7 weeks with 2 Gy fraction size, 5 days a week (46 Gy to primary and whole neck followed by 24 Gy after sparing the cord). The response to treatment was assessed by World Health Organization (WHO) criteria after one month of completion of treatment (Hoogstraten et al., 1979).

Patients were followed up after treatment and evaluated for survival. The primary endpoints were treatment response and overall survival (OS) from the date of diagnosis to the date of death from any cause and patients were censored who were alive on the date of last follow up examination.

Preparation of cDNA {#sec2-3}
-------------------

The tissue specimens of OSCC patients and controls were collected in TRIzol Reagent (Ambion, Life Technology) and immediately homogenized with T25 basic homogenizer (IKA Labortechnik, Stanfen, Germany). Total RNA was isolated according to TRIzol Reagent protocol and stored at -80°C for further use. The total RNA of each sample was reverse transcribed to cDNA using cDNA synthesis kit (Thermo Scientific, EU, Lithuania) according to the manufacturer's protocol.

Analysis of mRNA expression by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) {#sec2-4}
---------------------------------------------------------------------------------------------------------------

qRT-PCR analysis was performed according to the manufacturer's protocol (Takara SYBR Fast qPCR kit, Takara Biosystem). The qRT-PCR reactions were performed using Applied Biosystem 7900 HT real time PCR system and reactions were carried out in triplicates. Beta-actin was taken as an internal control and used to normalize ratio between samples. The primer sets specific for PEG10 (Forward: 5'-GACTCCGGCTTTGACACAACA-3', Reverse: 5'-AACGCTGGAGCCACCAGTAA-3') and beta actin (Forword: 5'-GCACAGAGCCTCGCCTT-3', Reverse: 5'-GTTGTCGACGACGAGCG-3') were used. An initial incubation of enzyme denaturation at 95°C for 10 minutes followed by 45 rounds of amplification at 95°C (10 sec) for denaturation, 58-65°C (10 sec) for annealing and 72°C (30 sec) for extension for performing qRT-PCR. Relative change in mRNA level between tumor and matched normal control tissue were calculated by using 2¯ΔΔct method.

Statistical analysis {#sec2-5}
--------------------

One way ANNOVA using Turkey's Multiple Comparison test was used to compare the mRNA expression levels between different groups in both cases and controls. Comparisons were made between categorical groups by chi-square (χ^2^) test. Survival curves were plotted compared by Log rank (Mantel-Cox: χ^2^) test using Kaplan-Meier method. Cox-regression analysis was conducted to find out independent prognostic factors of overall survival. A two-tailed p\<0.05 was considered statistically significant.

Results {#sec1-3}
=======

The demographic and clinicopathological characteristics of OSCC patients are summarized in ([table 1](#T1){ref-type="table"}). The age range was 22-72 years (mean ± SD, 44.9 ± 7.2 years) for OSCC patients and 21-70 years (mean ± SD, 42.1 ± 13.9 years) for controls. The number of male patients was 72.9% which was higher than the female patients. Majority of the patients had carcinoma of buccal mucosa (52.5 %) followed by tongue (24.6 %) as primary disease sites. It was observed that most of the patients (63.6%) had habit of tobacco chewing. The distributions of OSCC according to histopathological grading were 58 patients (49.2%) with well differentiated histology, 42 patients (39.8%) were moderately differentiated and 13 patients (11.0%) were poorly differentiated. Out of total 118 patients, T4 tumor size were the commonest (43.2%), Lymph node positive (66.1%), and advanced stage, (stage III and IV) (89.3%). qRT-PCR study revealed highly significant (p\<0.001) mRNA expression of PEG10 in OSCC patients cases as compared to matched controls. Moreover the mRNA expression of PEG10 was higher in 70.3% (83/118) patients and 29.7% (35/118) patients had low PEG10 mRNA expression ([Table 2](#T2){ref-type="table"}).

###### 

Demographic and Clinicopathological Characteristic of OSCC Patients (n=118)

  Characteristic /category          No. of patient (%)
  --------------------------------- --------------------
  Age (Years)                       
   20-30                            14 (11.8)
   31-40                            29 (24.6)
   41-50                            37 (31.4)
   51-60                            27 (22.9)
   61-70                            11 (9.3)
  Sex                               
   Female                           32 (27.1)
   Male                             86 (72.9)
  Tobacco Chewing                   
   No                               43 (36.4)
   Yes                              75 (63.6)
  Smoking                           
   No                               57 (48.3)
   Yes                              61 (51.7)
  Alcohol Consumption               
   No                               62 (52.5)
   Yes                              56 (47.5)
  Primary Site                      
   Buccal Mucosa                    62 (52.5)
   Oral tongue                      29 (24.6)
   Alveolus                         18 (15.3)
   Retromolartrigone                4 (3.4)
   Lips                             3 (2.5)
   Hard Palate                      2 (1.7)
  SCC Differentiation               
   Well                             58 (49.2)
   Moderate                         47 (49.8)
   Poor                             13 (11.1)
  Tumor Size                        
   T1                               5 (4.2)
   T2                               25 (21.2)
   T3                               37 (31.4)
   T4                               51 (43.2)
  Lymph node status                 
   N0                               39 (33.1)
   N1                               42(35.6)
   N2                               30 (25.4)
   N3                               7 (5.9)
  Stage                             
   Early                            12 (10.2)
   Advanced                         106 (89.8)
  Radiotherapy Treatment response   
   Responder's                      67 (56.8)
   Non-Responder's                  51 (43.2)

###### 

Correlation of PEG10 Gene Expression with the Clinicopathological Characteristics

  Variables               Category      Number of patients (%)   PEG10 mRNA expression (n, %) Low level of expression   high level of expression   P value
  ----------------------- ------------- ------------------------ ------------------------------------------------------ -------------------------- ---------------
  Total                                 118                      35 (29.7)                                              83 (70.3)                  
  SCC Differentiation     Well          58 (49.2)                19 (32.7)                                              39 (67.2)                  p= 0.6012
  Poor and Moderate       60 (50.8)     16 (26.7)                44 (73.3)                                                                         
  Tumor size              T1-T2         30 (25.4)                12 (40)                                                18 (60)                    p= 0.2285
  T3-T4                   88 (74.6)     23 (26.1)                65 (73.9)                                                                         
  Lymph node metastasis   Negative      40 (33.9)                19 (47.5)                                              21 (52.5)                  **p=0.0047**
  Positive                78 (66.1)     16 (20.5)                62 (79.5)                                                                         
  Stage                   Early stage   12 (10.2)                7 (58.3)                                               5 (41.7)                   **p= 0.0499**
  Advanced stage          106 (89.8)    28 (26.4)                78 (73.6)                                                                         

Significant p values were highlighted in bold.

The association between PEG10 mRNA expressions (Low and high) and clinicopathological characteristics was done using χ^2^ test and shown in ([Table 2](#T2){ref-type="table"}). Overexpression of PEG10 significantly correlated with lymph node metastasis (N1 and N2) vs lymph node negative (N0) (p=0.0047) and advanced Stage (III and IV) vs early stage (I and II) (p=0.049). Out of 118 patients, 67 (56.8%) patients were responders (complete response and partial response) and 51 patients (43.2%) were non responders (no response or progressive disease) ([Table 3](#T3){ref-type="table"}). The increase in expression of PEG10 mRNA was found to be highly significant (p\<0.001) in non responders when compared to responder OSCC patients.

###### 

Correlation of Clinicopathological Characteristics and PEG10 Expression with Overall Survival Using Cox's Regression Analysis (n=118)

  Predictors                               Number of patients(%)   Univariate (unadjusted)   Multivariate[\*\*](#t3f2){ref-type="table-fn"} (adjusted)                         
  ---------------------------------------- ----------------------- ------------------------- ----------------------------------------------------------- --------------------- -------
  Total                                    118                                                                                                                                 
  Age (yrs):                                                                                                                                                                   
   \<=45                                   67 (56.8)               1.0 (Ref)                                                                             1.0 (Ref)             
   \>45                                    51 (43.2)               1.411 (0.796-2.500)       0.238                                                       1.679 (0.905-3.118)   0.101
  Sex:                                                                                                                                                                         
   Female                                  32 (27.1)               1.0 (Ref)                                                                             1.0 (Ref)             
   Male                                    86 (72.9)               0.898 (0.481-1.677)       0.736                                                       0.625 (0.315-1.242)   0.18
  Primary site:                                                                                                                                                                
  Buccal mucosa                            62 (52.5)               1.0 (Ref)                                                                             1.0 (Ref)             
   Other[\*](#t3f1){ref-type="table-fn"}   56 (47.5)               1.166 (0.660-2.058)       0.596                                                       1.011 (0.561-1.825)   0.97
  SCC Grade:                                                                                                                                                                   
   WD                                      58 (49.2)               1.0 (Ref)                                                                             1.0 (Ref)             
   MD/PD                                   60 (50.8)               1.243 (0.700-2.207)       0.458                                                       1.317 (0.720-2.407)   0.371
  Tumor size:                                                                                                                                                                  
   T1/T2                                   30 (25.4)               1.0 (Ref)                                                                             1.0 (Ref)             
   T3/T4                                   88 (74.6)               1.725 (0.835-3.566)       0.141                                                       1.838 (0.813-4.153)   0.143
  Lymph node metastasis:                                                                                                                                                       
   Negative                                40 (33.9)               1.0 (Ref)                                                                             1.0 (Ref)             
   Positive                                78 (66.1)               2.515 (1.274-4.967)       0.008                                                       1.880 (0.835-4.231)   0.127
  Stage:                                                                                                                                                                       
   I/II                                    12 (10.2)               1.0 (Ref)                                                                             1.0 (Ref)             
   III/IV                                  106 (89.8)              2.702 (.836-8.731)        0.097                                                       1.032 (0.237-4.500)   0.966
  PEG 10:                                                                                                                                                                      
   Low                                     35 (29.7)               1.0 (Ref)                                                                             1.0 (Ref)             
   High                                    83 (70.3)               3.240 (1.505-6.979)       0.003                                                       2.982 (1.278-6.957)   0.011

CI, Confidence interval; Bold, Significant association (P\<0.05); Reference category, 1.0;

Others, Tongue, Alveolus, Floor of mouth, Lip, soft palate;

Adjusted for age, sex and Clinicopathological parameters.

The follow up time for patients that were used for analysis of PEG10 mRNA expression ranged from 10 month to 73 months (mean: 42.7 months, median: 45 months). During this period, 70 (59.3%) patients were alive and 48 (40.7%) were died. Survival rate for low and high expression of PEG10 were 77.1% and 51.8% respectively after a median follow up of 45 months. The PEG10 mRNA expression significantly correlated with survival and patient with high expression had shortened survival (log-rank, P = 0.003) as observed by Kaplan-Meier analysis ([Figure 1](#F1){ref-type="fig"}).

![Overall Survival Curve of OSCC Patients According of PEG10 Mrna Expression Using Kaplan-Meier Estimate with Log](APJCP-18-1513-g001){#F1}

To find out independent prognostic factors of overall survival, univariate and multivariate Cox regression analysis were done which is summarized in (Table 4). The univariate Cox regression analysis revealed significant (p=0.008, p=0.097 and p=0.003) association of overall survival with lymph node metastasis, stage and PEG10 mRNA expressions. In multivariate Cox regression analysis, the expression of PEG10 mRNA remained as a significant and independent predictor of survival after adjustment for age, sex, adverse habits and clinicopathological parameters, (HRR=2.982, 95% CI, 1.278-6.957, P=0.011).

Discussion {#sec1-4}
==========

Our research demonstrated significant increase in the mRNA expression of PEG10 in tissue samples from patients diagnosed with OSCC. The significant expression of PEG10 was also found previously in different types of human cancers such as hepatocellular carcinoma, gallbladder cancer, leukaemia, lung cancer, breast cancer, prostate cancer and pancreatic cancer (Liet al., 2006; Liu et al., 2011; Tsou et al., 2003; Li et al., 2016; Denget al., 2014).

Radiation therapy has an important contribution in the treatment of oral cancer but sometimes cancer cells do not respond to radiotherapy (Ishigami et al., 2007; Terakado et al., 2004). Current study demonstrated that the expression of PEG10 was higher in radioresistant tumor.

Several studies have demonstrated that PEG10 expression can be regulated by the proto-oncogene, c-MYC, via the binding of the c-MYC oncoprotein to the E-box-containing region of the first intron of PEG10 (Li et al., 2006; Ip et al., 2007; Jie et al., 2007). Previous reports indicated that the expression of PEG10 was significantly associated with poor survival in gall bladder carcinoma and hepatocellular carcinoma patients (Liu et al., 2014; Bang et al., 2014). It was also found that overexpression of PEG10 enhanced cell proliferation, migration and invasion in breast cancer (Li et al., 2016) and it plays a crucial role in human lung cancer proliferation, progression, prognosis and metastasis as well (Deng et al., 2014).

Liu et al., (2014) demonstrated that overexpression of PEG10 showed significant association with large tumor size, lymph node metastasis and advanced tumor stage and worse overall survival in patients with adenocarcinoma of gall bladder. In current study, we found the significant over expression of mRNA PEG10 in advanced stage and lymph node metastasis. This observation reflects the mRNA activity of PEG10 and its association with the tumor progression and poor prognosis in OSCC.

Currently, there are no specific biomarkers available that can reliably predict the outcome of radiotherapy treatment response in OSCC. Ishigami et al., (2006) revealed that inhibition of

PEG10 gene enhances radiosensitivity in human oral squamous carcinoma cell line. No single study on OSCC patients has revealed significant association of PEG10 mRNA expression with radiotherapy treatment response. In this study, significantly higher mRNA expression of PEG10 was found in non responder when compared to responders undergoing radiotherapy indicating that increase in the expression of PEG10 is associated with poor response in OSCC patients.

No previous study demonstrated any association between overexpression of PEG10 and clinical outcome as well as survival in oral cancer patients. In the current study, we observed the association between overexpression of mRNA PEG10 and clinical response and as well as poor survival. This implies that significance of using PEG10 as a predictive marker for response. These observations may further provide support that PEG10 is involved in the invasion and nodal metastasis of OSCC and may play a decisive role in the overall therapeutic outcome in OSCC.

We conducted the study in 118 oral cancer patients from India and found that PEG10 is overexpressed in OSCC patients. We also observed poor survival in patients where PEG10 were overexpressed as compared with low expression, suggesting the possibility of resistance to radiation in these patients and documenting the prognostic role of over expressed PEG10 in OSCC. However, the limitation of this study is the expression of PEG10 may or may not translate to patients of other ethnicities due to variability in genetic constitution and disease presentation differences. It requires more studies with larger patient populations to understand genetic variability of PEG10 expression among individuals in order to develop useful therapeutic approach and its correlation with radioresistance.

PEG10 may help in finding the pattern of radio-resistance in OSCC cases on the basis of clinicopathological parameters and could be found suitable for the use as a molecular marker to evaluate the response of OSCC undergoing radiotherapy. In conclusion, we observed significant increase in the mRNA expression of PEG10 in OSCC patients when compared to matched controls. We also found that overexpression of PEG10 gene was found to be significantly higher in lymph node positive when compared to lymph node negative OSCC patients. The PEG10 mRNA expression was significantly higher in non responders as compared to responders patient after radiotherapy treatment. Since the overexpression of PEG10 mRNA levels alter many signaling pathways found to be involved in the development and prognosis of OSCC, which may lead to the consideration that altered level of this gene may be helpful in predicting radiotherapy treatment response in OSCC patients. These results support that PEG10 could be used as potential biomarker for the OSCC patients undergoing radiotherapy treatment.
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